Lexicon Pharmaceuticals LXRX Pre-tax stock-based compensation cost
Pre-tax stock-based compensation cost at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's pre-tax stock-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's pre-tax stock-based compensation cost?
- Lexicon Pharmaceuticals (LXRX) reported pre-tax stock-based compensation cost of $3.1M in Q1 2026.
- How has Lexicon Pharmaceuticals's pre-tax stock-based compensation cost changed year-over-year?
- Lexicon Pharmaceuticals's pre-tax stock-based compensation cost increased by 3.3% year-over-year, from $3M to $3.1M.
- What is the long-term trend for Lexicon Pharmaceuticals's pre-tax stock-based compensation cost?
- Over 4 years (2021 to 2025), Lexicon Pharmaceuticals's pre-tax stock-based compensation cost has grown at a 4.0% compound annual growth rate (CAGR), from $10.6M to $12.4M.